Corner Therapeutics: Maraganore Hire Sales Trigger

🚀 Battle Card: Corner Therapeutics, Inc.

• John Maraganore, Strategic Adviser · 🔗 LinkedIn

• Corner just bolstered its leadership with a proven biotech founder to scale its DCITE platform commercialization – this Corner Therapeutics sales trigger signals investment in strategic growth. → Source

• Scaling cutting-edge immunotherapy R&D into clinical proof

• Securing strategic partnerships to fund next-in-human trials

• Primary: Corporate Strategy Consulting → Accelerate pipeline translation and investor readiness

• Expansion: BD Enablement Platform → Identify and engage biopharma partners faster

• HQ: Watertown, MA

• Employees: ≈ 50

• Rev: ≈ $10 M

• Website: cornertx.com

🤼 Competitive Intel

• GSK — Therapeutic Cell Therapies
• Unique edge: Global partnership network for co-development
• Evaluated by BD & Strategy for alliance capabilities

• BioNTech — mRNA-based Immunotherapies
• Unique edge: Rapid clinical translation and GMP scale-up
• Evaluated by R&D & CMO for trial acceleration

• Moderna — mRNA Platforms
• Unique edge: Fully integrated manufacturing at scale
• Evaluated by Ops & Finance for cost and speed

• SQZ Biotech — Cell Engineering Microfluidics
• Unique edge: Proprietary cell-loading tech for in vivo potency
• Evaluated by CMC & R&D for platform robustness

• Celyad Oncology — Allogeneic CAR-T
• Unique edge: Off-the-shelf T cell products
• Evaluated by Clinical Ops & Regulatory for go-to-market

✅ Do-Now Checklist

Next Step

🧠 Copy My Prompt for Personalized Cold Outreach

────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY   = ❑<your company>❑
OFFER_BRIEF   = ❑<1-line value>❑
PROOF_METRIC  = ❑<metric>❑
CTA_STYLE     = ❑quick_call | case_study❑
TONE          = ❑friendly | punchy❑

────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME        = John
COMPANY     = Corner Therapeutics, Inc.
DEPT        = R&D
SIZE        = ≈20
BOTTLENECK  = scaling cutting-edge immunotherapy R&D into clinical proof
EVENT       = Appoints Biotech Pioneer John Maraganore as Strategic Adviser
DETAIL      = appointing John Maraganore as Strategic Adviser
PAIN        = securing strategic partnerships to fund next-in-human trials
SRC         = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20250918054641&div=41152219
SIM_CO      = BioNTech
WIN_METRIC  = 40% faster partnership deals
NEXT_SIZE   = 50
EMP_EST     = ≈50
REV_EST     = ≈$10M

────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.

Validate any ≈ guesses via SRC.

EMAIL  (keep breaks):
Subject: ≈20-person R&D

John—noticed your R&D team is ≈20.

That’s when scaling cutting-edge immunotherapy R&D into clinical proof slows growth.

We helped BioNTech fix this with ❑<1-line value>❑.

Result: 40% faster partnership deals.  
<<CTA_STYLE=="quick_call" ? "Quick call?" : "Want the 2-min recap?">>

PS—next bottleneck hits ≈50.

DM ≤45 words, TONE:
Saw your post about appointing John Maraganore as Strategic Adviser — securing strategic partnerships to fund next-in-human trials.  
❑<1-line value>❑. ❑<metric>❑.  
<<CTA_STYLE=="quick_call" ? "Quick chat?" : "Send case study?">>